BACKGROUND: The extent to which mitochondrial DNA (mtDNA) content (also termed mtDNA copy number) in normal human cells is influenced by genetic factors has yet to be established. In addition, whether inherited variation of mtDNA content in normal cells contributes to cancer susceptibility remains unclear. Renal cell carcinoma accounts for 85% of all renal cancers. No studies have investigated the association between mtDNA content and the risk of renal cell carcinoma. METHODS: We first used a classic twin study design to estimate the genetic contribution to the determination of mtDNA content. mtDNA content was measured by quantitative real-time polymerase chain reaction in peripheral blood lymphocytes from 250 monozygotic twins, 92 dizygotic twins, and 33 siblings (ie, individual siblings of a pair of twins). We used biometric genetic modeling to estimate heritability of mtDNA content. We then used a case-control study with 260 case patients with renal cell carcinoma and 281 matched control subjects and multivariable logistic regression analysis to examine the association between mtDNA content in peripheral blood lymphocytes and the risk of renal cell carcinoma. All statistical tests were two-sided. RESULTS: The heritability (ie, proportion of phenotypic variation in a population that is attributable to genetic variation among individuals) of mtDNA content was 65% (95% confidence interval [CI] = 50% to 72%; P < .001). Case patients with renal cell carcinoma had a statistically significantly lower mtDNA content (1.18 copies) than control subjects (1.29 copies) (difference = 0.11, 95% CI = 0.03 to 0.17; P = .006). Low mtDNA content (ie, less than the median in control subjects) was associated with a statistically significantly increased risk of renal cell carcinoma, compared with high content (odds ratio = 1.53, 95% CI = 1.07 to 2.19). In a trend analysis, a statistically significant dose-response relationship was detected between lower mtDNA content and increasing risk of renal cell carcinoma (P for trend <.001). CONCLUSIONS: mtDNA content appears to have high heritability. Low mtDNA content appears to be associated with increased risk of renal cell carcinoma.
BACKGROUND: The extent to which mitochondrial DNA (mtDNA) content (also termed mtDNA copy number) in normal human cells is influenced by genetic factors has yet to be established. In addition, whether inherited variation of mtDNA content in normal cells contributes to cancer susceptibility remains unclear. Renal cell carcinoma accounts for 85% of all renal cancers. No studies have investigated the association between mtDNA content and the risk of renal cell carcinoma. METHODS: We first used a classic twin study design to estimate the genetic contribution to the determination of mtDNA content. mtDNA content was measured by quantitative real-time polymerase chain reaction in peripheral blood lymphocytes from 250 monozygotic twins, 92 dizygotic twins, and 33 siblings (ie, individual siblings of a pair of twins). We used biometric genetic modeling to estimate heritability of mtDNA content. We then used a case-control study with 260 case patients with renal cell carcinoma and 281 matched control subjects and multivariable logistic regression analysis to examine the association between mtDNA content in peripheral blood lymphocytes and the risk of renal cell carcinoma. All statistical tests were two-sided. RESULTS: The heritability (ie, proportion of phenotypic variation in a population that is attributable to genetic variation among individuals) of mtDNA content was 65% (95% confidence interval [CI] = 50% to 72%; P < .001). Case patients with renal cell carcinoma had a statistically significantly lower mtDNA content (1.18 copies) than control subjects (1.29 copies) (difference = 0.11, 95% CI = 0.03 to 0.17; P = .006). Low mtDNA content (ie, less than the median in control subjects) was associated with a statistically significantly increased risk of renal cell carcinoma, compared with high content (odds ratio = 1.53, 95% CI = 1.07 to 2.19). In a trend analysis, a statistically significant dose-response relationship was detected between lower mtDNA content and increasing risk of renal cell carcinoma (P for trend <.001). CONCLUSIONS: mtDNA content appears to have high heritability. Low mtDNA content appears to be associated with increased risk of renal cell carcinoma.
Authors: C Barthélémy; H Ogier de Baulny; J Diaz; M A Cheval; P Frachon; N Romero; F Goutieres; M Fardeau; A Lombès Journal: Ann Neurol Date: 2001-05 Impact factor: 10.422
Authors: M E Gahan; F Miller; S R Lewin; C L Cherry; J F Hoy; A Mijch; F Rosenfeldt; S L Wesselingh Journal: J Clin Virol Date: 2001-10 Impact factor: 3.168
Authors: Norman F Boyd; Gillian S Dite; Jennifer Stone; Anoma Gunasekara; Dallas R English; Margaret R E McCredie; Graham G Giles; David Tritchler; Anna Chiarelli; Martin J Yaffe; John L Hopper Journal: N Engl J Med Date: 2002-09-19 Impact factor: 91.245
Authors: Weigang Tang; Anindya Roy Chowdhury; Manti Guha; Li Huang; Thomas Van Winkle; Anil K Rustgi; Narayan G Avadhani Journal: Carcinogenesis Date: 2012-05-27 Impact factor: 4.944
Authors: Claudia R Oliva; Susan E Nozell; Anne Diers; Samuel G McClugage; Jann N Sarkaria; James M Markert; Victor M Darley-Usmar; Shannon M Bailey; G Yancey Gillespie; Aimee Landar; Corinne E Griguer Journal: J Biol Chem Date: 2010-09-24 Impact factor: 5.157
Authors: Lifang Hou; Zhong-Zheng Zhu; Xiao Zhang; Francesco Nordio; Matteo Bonzini; Joel Schwartz; Mirjam Hoxha; Laura Dioni; Barbara Marinelli; Valeria Pegoraro; Pietro Apostoli; Pier Alberto Bertazzi; Andrea Baccarelli Journal: Environ Health Date: 2010-08-09 Impact factor: 5.984